Back

현대바이오 KOSDAQ

048410

Suggest a tag

Watch

Notes Naver Finance

Upcoming shareholder meeting

Extraordinary

2026.10.23 DART

Meeting date 2026.12.09 10:00 Location 경상북도 김천시 아포읍 아포공단길 106 현대바이오사이언스㈜ 본사 2층

• 제1호 의안: 이사 선임의 건 (독립이사 김진석)
• 제2호 의안: 감사 선임의 건 (상근감사 조용호)
• 제3호 의안: 이사 보수한도 승인의 건 (제27기 이사 보수한도 : 5억원)
• 제4호 의안: 감사 보수한도 승인의 건 (제27기 감사 보수한도 : 8천만원)

Shareholder proposals

주주총회소집결의

2026.03.11 DART

주주측이 상근감사 홍철기 선임 요구
- (경영진에 대한 독립적인 감시 및 견제 기능 강화 목적)

Meeting voting results

Previous meeting results

Financial indicators

Market cap

5,047 × 100M KRW

PBR

4.89

PER

ROE

-29.47%

Dividend yield

Debt-to-equity ratio

18.1%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2026 Semiannual report (2026-06-30)

Controlling shareholders total

10.19%

Minority shareholders (excl. related parties)

83.56%

Large outside holders (1%+)

6.25% (8 people)

Treasury shares

0.00%

Total shareholders

71,064 people

Annual earnings Trend

Financial statements

Consolidated · includes subsidiaries

현대바이오 — Annual Consolidated Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	255.4 × 100M KRW	289.1 × 100M KRW	406.7 × 100M KRW	361 × 100M KRW	319.7 × 100M KRW	318.6 × 100M KRW	300.9 × 100M KRW	125.1 × 100M KRW	92.4 × 100M KRW	78.5 × 100M KRW	94.8 × 100M KRW	150.5 × 100M KRW	35.2 × 100M KRW
Operating profit	-83.5 × 100M KRW	6.5 × 100M KRW	13.6 × 100M KRW	-69.6 × 100M KRW	14.6 × 100M KRW	15.8 × 100M KRW	25.6 × 100M KRW	-45.4 × 100M KRW	-97.7 × 100M KRW	-263.5 × 100M KRW	-97.9 × 100M KRW	8.3 × 100M KRW	-181.6 × 100M KRW
Net income	-103.5 × 100M KRW	-31.1 × 100M KRW	7.1 × 100M KRW	-80.7 × 100M KRW	12.2 × 100M KRW	26.2 × 100M KRW	11.2 × 100M KRW	-82.6 × 100M KRW	-200.5 × 100M KRW	-158.1 × 100M KRW	-145 × 100M KRW	-69.3 × 100M KRW	-221.3 × 100M KRW
Operating margin	-32.69%	2.24%	3.33%	-19.29%	4.58%	4.97%	8.49%	-36.29%	-105.72%	-335.65%	-103.20%	5.54%	-516.32%
Balance sheet
Total assets	308.4 × 100M KRW	328.1 × 100M KRW	434.1 × 100M KRW	533.8 × 100M KRW	495 × 100M KRW	540.1 × 100M KRW	642.2 × 100M KRW	937.4 × 100M KRW	805.3 × 100M KRW	673.3 × 100M KRW	527.9 × 100M KRW	677 × 100M KRW	1,307.4 × 100M KRW
Total liabilities	90.4 × 100M KRW	103.2 × 100M KRW	188.1 × 100M KRW	351.7 × 100M KRW	186.1 × 100M KRW	135.2 × 100M KRW	164.6 × 100M KRW	414 × 100M KRW	189.6 × 100M KRW	90.9 × 100M KRW	75.2 × 100M KRW	282.7 × 100M KRW	200.1 × 100M KRW
Total equity	218 × 100M KRW	224.9 × 100M KRW	246 × 100M KRW	182.1 × 100M KRW	308.9 × 100M KRW	404.8 × 100M KRW	477.6 × 100M KRW	523.4 × 100M KRW	615.7 × 100M KRW	582.4 × 100M KRW	452.7 × 100M KRW	394.4 × 100M KRW	1,107.3 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-170.5 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-385.9 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	743.7 × 100M KRW
Investment indicators
ROE	-47.48%	-13.82%	2.89%	-44.31%	3.94%	6.47%	2.35%	-15.78%	-32.57%	-27.14%	-32.03%	-17.57%	-19.98%
Debt-to-equity ratio	41.46%	45.90%	76.44%	193.07%	60.24%	33.41%	34.47%	79.11%	30.79%	15.61%	16.61%	71.67%	18.07%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	-	-	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	341.2 × 100M KRW	-	-	356.9 × 100M KRW	-	-	348.5 × 100M KRW	-	-	68.1 × 100M KRW	439.9 × 100M KRW
Non-current assets	-	-	92.9 × 100M KRW	-	-	183.2 × 100M KRW	-	-	456.8 × 100M KRW	-	-	608.9 × 100M KRW	867.5 × 100M KRW
Current liabilities	-	-	97.1 × 100M KRW	-	-	114.4 × 100M KRW	-	-	166.5 × 100M KRW	-	-	274.9 × 100M KRW	195.2 × 100M KRW
Non-current liabilities	-	-	91 × 100M KRW	-	-	20.9 × 100M KRW	-	-	23.1 × 100M KRW	-	-	7.8 × 100M KRW	4.9 × 100M KRW
Equity attributable to owners	-	-	-	-	-	-	-	-	-	-	-	-	1,107.3 × 100M KRW
Share capital	-	-	151.5 × 100M KRW	-	-	168.6 × 100M KRW	-	-	193.3 × 100M KRW	-	-	199.1 × 100M KRW	480.2 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	-	592.2 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-	451.7 × 100M KRW
Retained earnings	-	-	-595 × 100M KRW	-	-	-633.3 × 100M KRW	-	-	-901.3 × 100M KRW	-	-	-195.7 × 100M KRW	-416.9 × 100M KRW
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	KRW 0

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

현대바이오 — Quarterly Consolidated Financial statements
Item	24/3	24/6	24/9	24/12	25/3	25/6	25/9	25/12	26/3	26/6
Income statement
Revenue	50.5 × 100M KRW	91.8 × 100M KRW	4.6 × 100M KRW	3.7 × 100M KRW	7.1 × 100M KRW	3.3 × 100M KRW	5.5 × 100M KRW	19.2 × 100M KRW	3.2 × 100M KRW	5.2 × 100M KRW
Operating profit	12.2 × 100M KRW	56.9 × 100M KRW	-33.2 × 100M KRW	-27.6 × 100M KRW	-42.8 × 100M KRW	-48.2 × 100M KRW	-46.2 × 100M KRW	-44.4 × 100M KRW	-46.7 × 100M KRW	-55.4 × 100M KRW
Net income	11.9 × 100M KRW	15.8 × 100M KRW	-51.3 × 100M KRW	-45.8 × 100M KRW	-61.4 × 100M KRW	-42.5 × 100M KRW	-70 × 100M KRW	-47.4 × 100M KRW	-53.1 × 100M KRW	-115.6 × 100M KRW
Operating margin	24.16%	61.99%	-722.70%	-754.93%	-604.24%	-1447.42%	-835.32%	-230.92%	-1436.92%	-1064.26%
Balance sheet
Total assets	537.3 × 100M KRW	760.2 × 100M KRW	709.7 × 100M KRW	677 × 100M KRW	1,423.9 × 100M KRW	1,198.1 × 100M KRW	1,166.2 × 100M KRW	1,307.4 × 100M KRW	1,291 × 100M KRW	1,313.1 × 100M KRW
Total liabilities	73.2 × 100M KRW	272.6 × 100M KRW	272.3 × 100M KRW	282.7 × 100M KRW	248.6 × 100M KRW	53.5 × 100M KRW	63.4 × 100M KRW	200.1 × 100M KRW	171.2 × 100M KRW	280 × 100M KRW
Total equity	464.1 × 100M KRW	487.6 × 100M KRW	437.4 × 100M KRW	394.4 × 100M KRW	1,175.3 × 100M KRW	1,144.6 × 100M KRW	1,102.8 × 100M KRW	1,107.3 × 100M KRW	1,119.8 × 100M KRW	1,033.1 × 100M KRW
Cash flow statement
Operating cash flow	-78.1 × 100M KRW	80.2 × 100M KRW	60.2 × 100M KRW	-	-34.2 × 100M KRW	-45.9 × 100M KRW	-35.1 × 100M KRW	-55.4 × 100M KRW	-20.5 × 100M KRW	-54.1 × 100M KRW
Investing cash flow	98.9 × 100M KRW	-268.7 × 100M KRW	-24.2 × 100M KRW	-	-158 × 100M KRW	-279.3 × 100M KRW	8.6 × 100M KRW	42.9 × 100M KRW	-120.3 × 100M KRW	45.2 × 100M KRW
Financing cash flow	2,174 × 10,000 KRW	193.5 × 100M KRW	-3,084 × 10,000 KRW	-	790.4 × 100M KRW	-192.9 × 100M KRW	-1.3 × 100M KRW	147.5 × 100M KRW	-1.7 × 100M KRW	98.2 × 100M KRW
Investment indicators
Debt-to-equity ratio	15.77%	55.92%	62.25%	71.67%	21.15%	4.68%	5.75%	18.07%	15.29%	27.10%
EPS	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	161.7 × 100M KRW	153.8 × 100M KRW	90.7 × 100M KRW	68.1 × 100M KRW	821 × 100M KRW	392 × 100M KRW	359.6 × 100M KRW	439.9 × 100M KRW	399.9 × 100M KRW	438 × 100M KRW
Non-current assets	375.6 × 100M KRW	606.4 × 100M KRW	618.9 × 100M KRW	608.9 × 100M KRW	602.9 × 100M KRW	806.1 × 100M KRW	806.6 × 100M KRW	867.5 × 100M KRW	891.1 × 100M KRW	875 × 100M KRW
Current liabilities	67.2 × 100M KRW	265.6 × 100M KRW	264.4 × 100M KRW	274.9 × 100M KRW	240.9 × 100M KRW	46.8 × 100M KRW	56.2 × 100M KRW	195.2 × 100M KRW	166.6 × 100M KRW	185.3 × 100M KRW
Non-current liabilities	6 × 100M KRW	7 × 100M KRW	7.9 × 100M KRW	7.8 × 100M KRW	7.7 × 100M KRW	6.8 × 100M KRW	7.2 × 100M KRW	4.9 × 100M KRW	4.7 × 100M KRW	94.7 × 100M KRW
Equity attributable to owners	464.1 × 100M KRW	487.6 × 100M KRW	437.4 × 100M KRW	-	1,175.3 × 100M KRW	1,144.6 × 100M KRW	1,102.8 × 100M KRW	1,107.3 × 100M KRW	1,119.8 × 100M KRW	1,033.1 × 100M KRW
Share capital	199.1 × 100M KRW	199.1 × 100M KRW	199.1 × 100M KRW	199.1 × 100M KRW	240.1 × 100M KRW	240.1 × 100M KRW	480.2 × 100M KRW	480.2 × 100M KRW	482.5 × 100M KRW	482.5 × 100M KRW
Capital surplus	30.6 × 100M KRW	30.7 × 100M KRW	30.7 × 100M KRW	-	832.3 × 100M KRW	832.3 × 100M KRW	592.2 × 100M KRW	592.2 × 100M KRW	620.3 × 100M KRW	622.4 × 100M KRW
Other equity	348.1 × 100M KRW	355.7 × 100M KRW	356.7 × 100M KRW	-	360 × 100M KRW	-299.6 × 100M KRW	-369.6 × 100M KRW	451.7 × 100M KRW	487 × 100M KRW	513.7 × 100M KRW
Retained earnings	-113.7 × 100M KRW	-97.9 × 100M KRW	-149.1 × 100M KRW	-195.7 × 100M KRW	-257.1 × 100M KRW	371.8 × 100M KRW	400 × 100M KRW	-416.9 × 100M KRW	-470 × 100M KRW	-585.6 × 100M KRW
Non-controlling interests	KRW 0	KRW 0	KRW 0	-	KRW 0	KRW 0	KRW 0	KRW 0	KRW 0	KRW 0

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Separate · this company only

현대바이오 — Annual Separate Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	213.2 × 100M KRW	273.6 × 100M KRW	320.6 × 100M KRW	304.9 × 100M KRW	277.1 × 100M KRW	264.9 × 100M KRW	249.2 × 100M KRW	123.6 × 100M KRW	90.3 × 100M KRW	77.9 × 100M KRW	94.8 × 100M KRW	150.5 × 100M KRW	35.2 × 100M KRW
Operating profit	-82.3 × 100M KRW	12.9 × 100M KRW	16.7 × 100M KRW	-72.1 × 100M KRW	19 × 100M KRW	23.7 × 100M KRW	31.2 × 100M KRW	-47.4 × 100M KRW	-94.1 × 100M KRW	-260.4 × 100M KRW	-93 × 100M KRW	22.5 × 100M KRW	-175 × 100M KRW
Net income	-96.6 × 100M KRW	-5.7 × 100M KRW	8.1 × 100M KRW	-90.5 × 100M KRW	9.7 × 100M KRW	25.9 × 100M KRW	16.6 × 100M KRW	-97 × 100M KRW	-219.3 × 100M KRW	-118.6 × 100M KRW	-141.5 × 100M KRW	-11 × 100M KRW	-173.4 × 100M KRW
Operating margin	-38.61%	4.73%	5.20%	-23.63%	6.84%	8.96%	12.54%	-38.31%	-104.13%	-334.27%	-98.12%	14.95%	-497.42%
Balance sheet
Total assets	302.2 × 100M KRW	329.2 × 100M KRW	431.5 × 100M KRW	505.5 × 100M KRW	487.2 × 100M KRW	511.3 × 100M KRW	624.9 × 100M KRW	903 × 100M KRW	749.2 × 100M KRW	665.5 × 100M KRW	527.3 × 100M KRW	734.7 × 100M KRW	1,330.3 × 100M KRW
Total liabilities	87.6 × 100M KRW	100.6 × 100M KRW	180.5 × 100M KRW	327.8 × 100M KRW	184.1 × 100M KRW	113.6 × 100M KRW	153.6 × 100M KRW	400.1 × 100M KRW	171.2 × 100M KRW	82 × 100M KRW	72.1 × 100M KRW	282.8 × 100M KRW	200.3 × 100M KRW
Total equity	214.7 × 100M KRW	228.6 × 100M KRW	251 × 100M KRW	177.7 × 100M KRW	303.1 × 100M KRW	397.7 × 100M KRW	471.2 × 100M KRW	502.9 × 100M KRW	578 × 100M KRW	583.5 × 100M KRW	455.2 × 100M KRW	451.9 × 100M KRW	1,130 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-163.9 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-391 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	743.7 × 100M KRW
Investment indicators
ROE	-45.02%	-2.50%	3.22%	-50.91%	3.19%	6.51%	3.52%	-19.29%	-37.94%	-20.32%	-31.08%	-2.43%	-15.35%
Debt-to-equity ratio	40.80%	43.98%	71.90%	184.49%	60.73%	28.56%	32.60%	79.55%	29.62%	14.06%	15.84%	62.57%	17.72%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	-	-	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	335.4 × 100M KRW	-	-	333.8 × 100M KRW	-	-	344.8 × 100M KRW	-	-	64.7 × 100M KRW	438.2 × 100M KRW
Non-current assets	-	-	96.1 × 100M KRW	-	-	177.4 × 100M KRW	-	-	404.4 × 100M KRW	-	-	670 × 100M KRW	892 × 100M KRW
Current liabilities	-	-	89.5 × 100M KRW	-	-	94.4 × 100M KRW	-	-	164.2 × 100M KRW	-	-	275 × 100M KRW	195.3 × 100M KRW
Non-current liabilities	-	-	91 × 100M KRW	-	-	19.2 × 100M KRW	-	-	7 × 100M KRW	-	-	7.8 × 100M KRW	4.9 × 100M KRW
Share capital	-	-	151.5 × 100M KRW	-	-	168.6 × 100M KRW	-	-	193.3 × 100M KRW	-	-	199.1 × 100M KRW	480.2 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	-	592.2 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-	386.3 × 100M KRW
Retained earnings	-	-	-611.2 × 100M KRW	-	-	-662.1 × 100M KRW	-	-	-962.1 × 100M KRW	-	-	-155.2 × 100M KRW	-328.7 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

현대바이오 — Quarterly Separate Financial statements
Item	24/3	24/6	24/9	24/12	25/3	25/6	25/9	25/12	26/3	26/6
Income statement
Revenue	-	-	-	-	-	-	-	-	3.2 × 100M KRW	5.2 × 100M KRW
Operating profit	-	-	-	-	-	-	-	-	-45.6 × 100M KRW	-53.9 × 100M KRW
Net income	-	-	-	-	-	-	-	-	-47.1 × 100M KRW	-88.4 × 100M KRW
Operating margin	-	-	-	-	-	-	-	-	-1403.82%	-1035.93%
Balance sheet
Total assets	-	-	-	-	-	-	-	-	1,287.7 × 100M KRW	1,334.5 × 100M KRW
Total liabilities	-	-	-	-	-	-	-	-	171.4 × 100M KRW	280.1 × 100M KRW
Total equity	-	-	-	-	-	-	-	-	1,116.3 × 100M KRW	1,054.3 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-19.5 × 100M KRW	-52.6 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-120.3 × 100M KRW	36 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-1.7 × 100M KRW	98.2 × 100M KRW
Investment indicators
Debt-to-equity ratio	-	-	-	-	-	-	-	-	15.35%	26.57%
EPS	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	-	64.7 × 100M KRW	-	-	-	438.2 × 100M KRW	399.3 × 100M KRW	429.3 × 100M KRW
Non-current assets	-	-	-	670 × 100M KRW	-	-	-	892 × 100M KRW	888.4 × 100M KRW	905.2 × 100M KRW
Current liabilities	-	-	-	275 × 100M KRW	-	-	-	195.3 × 100M KRW	166.7 × 100M KRW	185.4 × 100M KRW
Non-current liabilities	-	-	-	7.8 × 100M KRW	-	-	-	4.9 × 100M KRW	4.7 × 100M KRW	94.7 × 100M KRW
Share capital	-	-	-	199.1 × 100M KRW	-	-	-	480.2 × 100M KRW	482.5 × 100M KRW	482.5 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	592.2 × 100M KRW	620.3 × 100M KRW	622.4 × 100M KRW
Other equity	-	-	-	-	-	-	-	386.3 × 100M KRW	389.3 × 100M KRW	413.6 × 100M KRW
Retained earnings	-	-	-	-155.2 × 100M KRW	-	-	-	-328.7 × 100M KRW	-375.8 × 100M KRW	-464.3 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Legacy summaries and estimates; may include data with unverified accounting scope.

현대바이오 — Annual Legacy summary & estimates Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023 Consolidated	2024 Consolidated	2025 Consolidated
Income statement
Revenue	255.4 × 100M KRW	289.1 × 100M KRW	406.7 × 100M KRW	361 × 100M KRW	319.7 × 100M KRW	318.6 × 100M KRW	300.9 × 100M KRW	125.1 × 100M KRW	92.4 × 100M KRW	78.5 × 100M KRW	94.8 × 100M KRW	150.5 × 100M KRW	35.2 × 100M KRW
Operating profit	-83.5 × 100M KRW	6.5 × 100M KRW	13.6 × 100M KRW	-69.6 × 100M KRW	14.6 × 100M KRW	15.8 × 100M KRW	25.6 × 100M KRW	-45.4 × 100M KRW	-97.7 × 100M KRW	-263.5 × 100M KRW	-97.9 × 100M KRW	8.3 × 100M KRW	-181.6 × 100M KRW
Net income	-103.5 × 100M KRW	-31.1 × 100M KRW	7.1 × 100M KRW	-80.7 × 100M KRW	12.2 × 100M KRW	26.2 × 100M KRW	11.2 × 100M KRW	-82.6 × 100M KRW	-200.5 × 100M KRW	-158.1 × 100M KRW	-145 × 100M KRW	-69.3 × 100M KRW	-221.3 × 100M KRW
Operating margin	-32.69%	2.24%	3.33%	-19.29%	4.58%	4.97%	8.49%	-36.29%	-105.72%	-335.65%	-103.20%	5.54%	-516.32%
Balance sheet
Total assets	-	-	-	-	-	-	-	-	-	-	527.9 × 100M KRW	677 × 100M KRW	1,307.4 × 100M KRW
Total liabilities	90.4 × 100M KRW	103.2 × 100M KRW	188.1 × 100M KRW	351.7 × 100M KRW	186.1 × 100M KRW	135.2 × 100M KRW	164.6 × 100M KRW	414 × 100M KRW	189.6 × 100M KRW	90.9 × 100M KRW	75.2 × 100M KRW	282.7 × 100M KRW	200.1 × 100M KRW
Total equity	218 × 100M KRW	224.9 × 100M KRW	246 × 100M KRW	182.1 × 100M KRW	308.9 × 100M KRW	404.8 × 100M KRW	477.6 × 100M KRW	523.4 × 100M KRW	615.7 × 100M KRW	582.4 × 100M KRW	452.7 × 100M KRW	394.4 × 100M KRW	1,107.3 × 100M KRW
Investment indicators
ROE	-47.48%	-13.82%	2.89%	-44.31%	3.94%	6.47%	2.35%	-15.78%	-32.57%	-27.14%	-32.03%	-17.57%	-19.98%
Debt-to-equity ratio	41.46%	45.90%	76.44%	193.07%	60.24%	33.41%	34.47%	79.11%	30.79%	15.61%	16.61%	71.67%	18.07%
Separate total assets	-	-	-	-	-	-	-	-	-	-	527.3 × 100M KRW	734.7 × 100M KRW	1,330.3 × 100M KRW
EPS	-	-	-	-	-	-	-	-	-	KRW -189	KRW -172	KRW -82	KRW -235
PER	-	-	-	-	-	-	-	-	-	-68.33×	-71.69×	-86.14×	-21.11×
PBR	-	-	-	-	-	-	-	-	-	18.69	22.98	15.14	4.31
Dividend per share	-	-	-	-	-	-	-	-	-	-	-	-	-

현대바이오 — Quarterly Legacy summary & estimates Financial statements
Item	24/3 Consolidated	24/6 Consolidated	24/9 Consolidated	24/12 Consolidated	25/3 Consolidated	25/6 Consolidated	25/9 Consolidated	25/12 Consolidated	26/3 Consolidated	26/6 Consolidated
Income statement
Revenue	50.5 × 100M KRW	91.8 × 100M KRW	4.6 × 100M KRW	3.7 × 100M KRW	7.1 × 100M KRW	3.3 × 100M KRW	5.5 × 100M KRW	19.2 × 100M KRW	3.2 × 100M KRW	5.2 × 100M KRW
Operating profit	12.2 × 100M KRW	56.9 × 100M KRW	-33.2 × 100M KRW	-27.6 × 100M KRW	-42.8 × 100M KRW	-48.2 × 100M KRW	-46.2 × 100M KRW	-44.4 × 100M KRW	-46.7 × 100M KRW	-55.4 × 100M KRW
Net income	11.9 × 100M KRW	15.8 × 100M KRW	-51.3 × 100M KRW	-45.8 × 100M KRW	-61.4 × 100M KRW	-42.5 × 100M KRW	-70 × 100M KRW	-47.4 × 100M KRW	-53.1 × 100M KRW	-115.6 × 100M KRW
Operating margin	24.16%	61.99%	-722.70%	-754.93%	-604.24%	-1447.42%	-835.32%	-230.92%	-1436.92%	-1064.26%
Balance sheet
Total assets	537.3 × 100M KRW	760.2 × 100M KRW	709.7 × 100M KRW	677 × 100M KRW	1,423.9 × 100M KRW	1,198.1 × 100M KRW	1,166.2 × 100M KRW	1,307.4 × 100M KRW	1,291 × 100M KRW	1,313.1 × 100M KRW
Total liabilities	73.2 × 100M KRW	272.6 × 100M KRW	272.3 × 100M KRW	282.7 × 100M KRW	248.6 × 100M KRW	53.5 × 100M KRW	63.4 × 100M KRW	200.1 × 100M KRW	171.2 × 100M KRW	280 × 100M KRW
Total equity	464.1 × 100M KRW	487.6 × 100M KRW	437.4 × 100M KRW	394.4 × 100M KRW	1,175.3 × 100M KRW	1,144.6 × 100M KRW	1,102.8 × 100M KRW	1,107.3 × 100M KRW	1,119.8 × 100M KRW	1,033.1 × 100M KRW
Investment indicators
Debt-to-equity ratio	15.77%	55.92%	62.25%	71.67%	21.15%	4.68%	5.75%	18.07%	15.29%	27.10%
EPS	-	-	-	-	-	-	-	-	-	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Property holdings

Total book value

11 × 100M KRW

Total assessed land value

31 × 100M KRW

Ratio to market cap

0.2%

Land

1 records

Buildings

1 records

Category	Location	Use	Area	Book value	Assessed land value
Land Unverified	경북 김천시 아포농공단지 내	본사 및 생산공장	16,204m²	11 × 100M KRW	17 × 100M KRW
Building Unverified	경북 김천시 아포농공단지 내	본사 및 생산공장	-	-	15 × 100M KRW

Ownership structure

Is a listed company shown as unlisted?

Corporate shareholders

Corporate and institutional holders identified in collected disclosures. This is not a complete shareholder register. Reporting-group holdings may overlap with individual holdings.

Business report analysis

Analysis date 2026.04.26 22:06 | Based on 2025 Annual report

Unverified Original business report

사업 개요

현대바이오사이언스는 2000년 5월 25일 현대전자로부터 분사하여 설립된 바이오 제약 및 코스메슈티컬 기업으로, 신약 개발과 기능성 화장품 사업을 병행하고 있습니다.
2012년부터 바이오 사업을 추진해 왔으며, 주력 산업은 바이오 의약품 개발 및 화장품 제조·판매입니다.

주요 매출원

연결재무제표 기준 당기 매출액은 약 35억원으로, 전기 약 151억원 대비 크게 감소했습니다.
영업보고서상 별도 표로 세부 제품 매출 구성은 제시되지 않았고, 본문상 기술거래 매출이 당기에 발생하지 않아 매출이 감소했다고 설명합니다.
영업부문별로는 당기 매출액이 바이오 부문 약 35억원, IT 부문 0원이며, 전기에는 바이오 부문 약 151억원, IT 부문 0원이었습니다.

원가 구조 / 비용 특성

당기 연결 기준 매출총이익은 약 2억원으로 매출총이익률이 매우 낮았고, 영업이익은 약 -182억원으로 적자 전환했습니다.
본문에서는 매출 감소와 함께 임상시험 준비 등을 위한 경상개발비 증가가 손실 확대의 주요 원인이라고 설명합니다.

자회사

Hyundai IT America Corp.: 디스플레이 판매, 해외판매 관련
비타브리드코리아㈜: 바이오제품 판매, 국내판매 관련
Hyundai Bioscience USA inc: 연구개발, 해외진출 관련
회사가 보유한 자회사 수는 3개입니다.

차입 구조

해당사항 없음.

Employees

72 people

Subsidiaries

3 items

Material subsequent events

해당사항 없음.

Articles of incorporation analysis

Analysis date 2026.06.20 19:25 | Last amended 2019.03.25

Unverified Original articles of incorporation

주주친화

분기배당: 이사회 결의로 3월·6월·9월 말일 주주에게 분기배당을 할 수 있음 (제55조)

주주비친화

집중투표제 명시적 배제: 2인 이상의 이사를 선임하는 경우 상법 제382조의2의 집중투표제를 적용하지 않아 소수주주의 이사 선임권을 약화시킴 (제33조③)
이사회 결의만으로 2,000억원 전환사채 제3자 배정: 경영상 목적, 외국인 투자, 긴급 자금조달 등을 이유로 주주 외의 자에게 전환사채 발행 가능 (제17조①)
이사회 결의만으로 2,000억원 신주인수권부사채 제3자 배정: 전환사채 발행 사유와 동일한 경우 주주 외의 자에게 BW 발행 가능 (제18조①)
이사 임기 3년 고정: 상법상 최장 수준의 임기를 정해 이사회 교체 속도를 늦출 수 있음 (제34조①)

기타 주목 조항

보궐선임 이사 임기: 보궐선임된 이사의 임기는 전임자의 잔여기간으로 함 (제34조③)
감사 1인 체제: 회사는 1인의 감사를 둠 (제44조)
제3자배정 신주 발행: 장기 발전, 신규사업, 사업목적 확대 또는 긴급 자금조달 등을 위해 발행주식총수의 90% 범위에서 제3자에게 신주 배정 가능 (제10조②④)

Board of directors

Number of directors

3–10 people

Director term

3 years (Fixed)

Remaining term for replacements

Staggered board

None

Cumulative voting

Separate chair and CEO

Gender diversity requirement

Auditors

Number of auditors

1–1 people

Auditor term

3 years (Fixed)

Shareholder meetings and dividends

Meeting notice period

14 days

Written voting

Electronic voting

Dividend record date

매결산기말

Third-party allotment limit by board resolution alone

Convertible bonds (CB)

2,000 × 100M KRW

Bonds with warrants (BW)

2,000 × 100M KRW

Compensation basis

Director: 이사의 보수한도는 주주총회의 결의로 정한다.
Auditors: 감사의 보수와 퇴직금은 이사의 보수와 퇴직금 규정을 준용하며, 감사 보수 의안은 이사 보수 의안과 구분하여 상정·의결한다.
Retirement payments: 이사 및 감사의 퇴직금은 주주총회의 결의를 거친 임원퇴직금지급규정에 의한다.

Executive compensation

Based on 2025 Annual report

Total compensation

4 × 100M KRW

Executives

5 people

Average per executive

8,520 × 10,000 KRW

Total dividends

Compensation / dividends

No dividend

Controlling shareholders

Name	Relationship	Age	Ownership
씨앤팜	Self	-	10.04%
김연진	최대주주의 임원	-	0.10%
진근우	발행회사의 대표이사	-	0.05%
조용호	발행회사의 감사	-	0.05%

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
씨앤팜	12.05%	11,632,282	0.00%	주식담보계약 변경	일반	2026-08-06
씨앤팜	12.05%	11,632,282	0.00%	주식담보계약 변경	일반	2026-07-22
씨앤팜	12.05%	11,632,282	+0.12%	발행회사의 전환사채 매도청구권 행사자 지정	일반	2026-06-30
씨앤팜	11.93%	11,517,914	0.00%	주식담보계약 변경	일반	2026-06-19
씨앤팜	11.93%	11,517,914	-0.03%	주식담보계약 변경	일반	2026-06-12
삼성자산운용	4.00%	3,860,758	-1.01%	매매로 인한 변동보고의무 발생	약식	2026-05-29
씨앤팜	11.96%	11,517,914	0.00%	1. 주식담보계약 체결 2. 주식담보계약 해지	일반	2026-04-23
씨앤팜	11.96%	11,517,914	0.00%	주식담보계약 변경	일반	2026-03-26
삼성자산운용	5.01%	4,815,404	+5.01%	매매로 인한 신규보고의무 발생	약식	2026-03-12
씨앤팜	11.96%	11,517,914	0.00%	1. 주식담보계약 체결 2. 주식담보계약 변경	일반	2026-03-06
씨앤팜	11.96%	11,517,914	0.00%	1. 교환대상주식 관리계약 체결 2. 전환사채 조기상환 후 소각 3. 주식담보계약 해지	일반	2026-01-23
씨앤팜	11.96%	11,517,914	0.00%	현물출자, 주식담보 연장계약 체결	일반	2025-12-19
씨앤팜	11.96%	11,517,914	0.00%	담보주식 수량변경	일반	2025-11-25
씨앤팜	11.96%	11,517,914	0.00%	- 주식담보 계약체결 - 주식담보 대출상환	일반	2025-11-12
씨앤팜	11.96%	11,517,914	+0.24%	- 발행회사의 전환사채 매도청구권 관련 옵션계약 체결 - 주식담보 계약연장	일반	2025-10-16
씨앤팜	11.72%	11,259,472	0.00%	주식담보 대출상환, 계약연장	일반	2025-09-24
씨앤팜	11.72%	11,259,472	0.00%	주식담보 계약연장	일반	2025-09-16
씨앤팜	11.72%	11,259,472	0.00%	무상증자, 교환사채 조기상환	일반	2025-08-19
씨앤팜	11.72%	5,629,736	-1.00%	교환사채의 교환권 행사, 주식담보 조정	일반	2025-07-18
씨앤팜	12.72%	6,109,300	0.00%	교환가액 조정, 주식담보 계약 연장	일반	2025-07-10
씨앤팜	12.72%	6,109,300	0.00%	현물출자, 주식담보 계약 연장	일반	2025-07-02
씨앤팜	12.72%	6,109,300	0.00%	현물출자 계약 체결, 주식담보 계약 연장, 담보대출 일부 상환	일반	2025-06-20
씨앤팜	12.72%	6,109,300	0.00%	주식담보 계약 체결	일반	2025-05-16
씨앤팜	12.72%	6,109,300	0.00%	씨앤팜 8EB 교환가격 조정에 따른 예탁주식수 변동	일반	2025-05-09
씨앤팜	12.72%	6,109,300	0.00%	주식담보 계약 연장	일반	2025-04-30
씨앤팜	12.72%	6,109,300	0.00%	주식담보 수량 변경	일반	2025-04-18
씨앤팜	12.72%	6,109,300	0.00%	- 주식담보 연장 및 신규 계약 체결 - 주식담보 수량 변경 - 담보계약 일부 및 전부 상환 - 교환대상주식 관리계약 체결	일반	2025-04-09
씨앤팜	12.72%	6,109,300	-0.20%	- 임원의 퇴임에 따른 특별관계자 제외 - 주식담보 연장 및 추가제공 - 담보대출 일부 및 전부 상환	일반	2025-04-01
씨앤팜	12.92%	6,202,447	0.00%	주식담보 신규 및 연장 계약 체결, 담보대출 일부 상환	일반	2025-03-21
씨앤팜	12.92%	6,202,447	+0.01%	- 유상증자 신주 입고 - 주가변동에 따른 주식담보 추가 제공	일반	2025-03-07
씨앤팜	12.91%	5,140,868	0.00%	주식담보 신규 및 변경계약 체결	일반	2025-02-11
씨앤팜	12.91%	5,140,868	0.00%	주식담보 상환 및 신규 계약 체결	일반	2025-01-20
씨앤팜	12.91%	5,140,868	0.00%	주식담보 상환 및 신규 계약 체결	일반	2025-01-13
씨앤팜	12.91%	5,140,868	0.00%	주식담보 연장계약 체결	일반	2024-12-30
씨앤팜	12.91%	5,140,868	0.00%	주식담보 연장계약 체결	일반	2024-12-20
씨앤팜	12.91%	5,140,868	0.00%	주식담보 수량 변경	일반	2024-11-22
씨앤팜	12.91%	5,140,868	0.00%	주식담보 신규 및 연장 계약 체결	일반	2024-11-19
씨앤팜	12.91%	5,140,868	0.00%	주식담보 신규 및 연장 계약 체결	일반	2024-10-18
씨앤팜	12.91%	5,140,868	0.00%	주식담보 연장계약 체결	일반	2024-10-11
씨앤팜	12.91%	5,140,868	0.00%	주식담보 연장계약 체결	일반	2024-09-27
씨앤팜	12.91%	5,140,868	-0.14%	특별관계자 주식 수 변동 및 주식담보계약 체결	일반	2024-09-13

Major shareholders

Major shareholders (4 people)

Based on 2025 Business report

Name	Shares owned	Ownership	Relationship
씨앤팜	9,637,930	10.04%	기타
김성권	2,044,000	2.13%	기타
현대에이디엠바이오	1,426,394	1.49%	기타
정수용	1,338,000	1.39%	기타

Auditors

Analysis date 2026.10.02 23:00

Auditor	Type	Term start	Term end	Tenure	D-day
조용호	Auditor	-	2024.03.31	5 years	Expired

Executives

Name	Position	Category	Age	Term end
김경일	연구고문	Inside director	Age 68	D-512
김진석	사외이사	Outside director	Age 64	Expired
배병준	사장	미등기	Age 60	-
조용호	감사	감사	Age 59	Expired
정영권	부회장	미등기	Age 59	-
이재관	상무	미등기	Age 59	-
김일선	상무	미등기	Age 54	-
최동수	전무	미등기	Age 54	-
강재은	상무	미등기	Age 53	-
정진환	부사장	Inside director	Age 53	D-512
김수환	전무	미등기	Age 50	-
엄성용	상무	미등기	Age 49	-
이지은	상무	미등기	Age 48	-
진근우	대표이사	Inside director	Age 46	D-512

DART disclosures

Loading disclosures…

Activism & governance

Board and audit Importance 3 2026.10.25 11:30

현대바이오, 이사·감사 선임 안건 위한 임시주총 소집

현대바이오는 지난 3월 정기주주총회에서 처리되지 못한 이사·감사 선임 안건을 다루기 위해 임시주주총회를 소집했다. 김진석 후보 재선임과 조용호 후보 신규 선임 안건이 상정됐다.

Shareholder perspective 이사와 감사 선임은 이사회 구성과 감독 기능에 영향을 미치는 주주총회 안건으로, 의결 결과가 회사의 지배구조에 영향을 줄 수 있다.

현대바이오 KOSDAQ

Upcoming shareholder meeting Collapse Upcoming shareholder meeting

Shareholder proposals Collapse Shareholder proposals

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Consolidated

Separate

Legacy summary & estimates

Property holdings Collapse Property holdings

Ownership structure Collapse Ownership structure

Corporate shareholders Collapse Corporate shareholders

Business report analysis Collapse Business report analysis

사업 개요

주요 매출원

원가 구조 / 비용 특성

자회사

차입 구조

Articles of incorporation analysis Collapse Articles of incorporation analysis

주주친화

주주비친화

기타 주목 조항

Board of directors

Auditors

Shareholder meetings and dividends

Third-party allotment limit by board resolution alone

Compensation basis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Major shareholders Collapse Major shareholders

Major shareholders (4 people)

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures

Activism & governance Collapse Activism & governance

현대바이오, 이사·감사 선임 안건 위한 임시주총 소집

Upcoming shareholder meeting

Shareholder proposals

Meeting voting results

Financial indicators

Share price history

Shareholder distribution

Annual earnings Trend

Financial statements

Property holdings

Ownership structure

Corporate shareholders

Business report analysis

Articles of incorporation analysis

Executive compensation

Controlling shareholders

Holders of 5% or more

Major shareholders

Auditors

Executives

DART disclosures

Activism & governance